Mesoblast Limited Sponsored ADR MESO 深 沪
交易中 05-11 10:30:14 美东时间
14.68
-0.070
-0.47%
华盛通- 最 高15.82
- 今 开14.63
- 成交量 4.67万股
- 最 低 14.51
- 昨 收 14.75
- 总市值 190.84万
- 52周最高 21.50
- 市盈率 静 --
- 换手率 35.91%
- 52周最低 9.88
- 委 比 13.04%
- 总股本 0.00亿
- 历史最高 30.927
- 量 比 3.05
- 振 幅 8.88%
- 历史最低 0.9703
- 每 手 1
- 风险率 2.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Alpha Buying: Insider Conviction in High-Risk Biotech
Insider buying matters in every industry, but it carries a special weight in bi...
05-08 00:04
Earnings Scheduled For February 26, 2026
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
Mesoblast Touts High Survival Rates For FDA-Approved Cell Therapy
Mesoblast shares fall after new Ryoncil data show high survival in severe GVHD. Company plans adult trial as analysts keep Hold rating and stock trades near key levels.
02-12 21:11
Mesoblast Stock Rises On Strong Year‑Over‑Year Growth In Ryoncil Sales
Mesoblast reported strong year‑over‑year growth in December quarter sales of its flagship therapy, Ryoncil.
01-10 01:34
Mesoblast Ltd Files for Offering of Upto $250M ADS Representing Ordinary Shares
-SEC Filing
2025-12-31 19:34
Jefferies Upgrades Mesoblast to Buy
Jefferies analyst David Stanton upgrades Mesoblast (NASDAQ:MESO) from Hold to Buy.
2025-11-25 21:39
澳洲生物制药公司Mesoblast二季度营收飙升66%
澳洲生物制药公司Mesoblast（OTCPK：MEOBF）第二季度营收飙升66%至2190万美元，主要受瑞昂西（Ryoncil）强劲销售驱动。该疗法是FDA批准的首个用于儿童类固醇难治性急性移植物抗宿主病的治疗方案。 海量资讯、精准解读，尽在新浪财经APP 责任编辑：张俊 SF065
2025-10-07 22:40
Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD
Mesoblast updates on FDA interactions for Revascor and Ryoncil, with positive commercial launch progress for Ryoncil in treating SR-aGvHD.
2025-06-12 01:24
Maxim Group Upgrades Mesoblast to Buy, Announces $12 Price Target
Maxim Group analyst Jason McCarthy upgrades Mesoblast (NASDAQ:MESO) from Hold to Buy and announces $12 price target.
2024-09-24 21:01
Jefferies Upgrades Mesoblast to Buy
Jefferies analyst David Stanton upgrades Mesoblast (NASDAQ:MESO) from Hold to Buy.
2024-08-29 23:27
